Lucid Diagnostics (LUCD)
(Delayed Data from NSDQ)
$0.92 USD
-0.05 (-5.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $0.91 -0.01 (-1.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.92 USD
-0.05 (-5.01%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $0.91 -0.01 (-1.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Avanos Medical (AVNS) Q3 Earnings Meet Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 0% and 2.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CVRx (CVRX) delivered earnings and revenue surprises of -26.67% and 0.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
by Zacks Equity Research
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.